{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "16380829",
  "DateCompleted": {
    "Year": "2006",
    "Month": "05",
    "Day": "10"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "11",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0097-0549",
      "JournalIssue": {
        "Volume": "36",
        "Issue": "2",
        "PubDate": {
          "Year": "2006",
          "Month": "Feb"
        }
      },
      "Title": "Neuroscience and behavioral physiology",
      "ISOAbbreviation": "Neurosci Behav Physiol"
    },
    "ArticleTitle": "A functional continuum of regulatory anxiety-enhancing peptides. The search for complexes providing the optimal basis for developing inhibitory therapeutic agents.",
    "Pagination": {
      "StartPage": "157",
      "EndPage": "162",
      "MedlinePgn": "157-62"
    },
    "Abstract": {
      "AbstractText": [
        "Regulatory peptides are actively involved in controlling most physiological processes. One such function is regulation of the level of anxiety and panic states. We report here a meta-analysis of data published from 1960 to 2004 on the effects of anxiety-enhancing regulatory peptides. The resulting database was used to investigate the organization and functioning of the anxiogenic regulatory peptide system. Using vector representation of the effects of these peptides, the spectra of physiological effects which might be provoked by each anxiety- and fear-increasing regulatory peptide alone and in combination were evaluated. Complexes of regulatory peptides with anxiogenic profiles with the greatest potential for the further experimental development of inhibitory pharmacological agents were identified."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "M. V. Lomonosov Moscow State University, 119899 Moscow, Russia."
          }
        ],
        "LastName": "Koroleva",
        "ForeName": "S V",
        "Initials": "SV"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Ashmarin",
        "ForeName": "I P",
        "Initials": "IP"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Meta-Analysis"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Neurosci Behav Physiol",
    "NlmUniqueID": "0330471",
    "ISSNLinking": "0097-0549"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Anxiety Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Peptides"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Anxiety Agents"
    },
    {
      "QualifierName": [
        "drug therapy",
        "metabolism"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Design"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "classification",
        "metabolism"
      ],
      "DescriptorName": "Peptides"
    }
  ]
}